Pterygium thickness did not meaningfully correlate with keratometry, astigmatism, irregularity indices, or most HOA metrics, suggesting depth contributes less to optical degradation than planar extent ...
Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...
An offline, point-of-care algorithm on a smartphone fundus camera generated disease-specific outputs without cloud connectivity, addressing a major deployment barrier in low-resource screening ...
To explore what the veligrotug approval means for patients and practice, Ophthalmology Times posed the same questions to several TED specialists, including the following: Raymond S. Douglas, MD, PhD, ...
4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...
Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...
Geographic atrophy can emerge during stable anti-VEGF regimens for bilateral wet AMD, requiring deliberate surveillance and patient counseling rather than “treat-and-forget” follow-up. Coordinating ...
In this podcast, experts Mary Qiu, MD; Paul Singh, MD; and Danica J. Marrelli, OD, FAAO; discuss interventional glaucoma. This more proactive management approach aims to minimize the challenges of ...
Peripheral retinal lesions occurred in 54.4% of highly myopic pediatric eyes, were bilateral in 64.2%, and increased in prevalence and multiplicity with age and more negative spherical equivalent.
How faricimab reshapes DME care: trial vs real-world durability, Ang2/VEGF clues, when to switch, and how AI-guided OCT may help. This episode, titled “Dosing Frequency Across Retinal Vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results